ATHE - Alterity jumps after promising data on Parkinson's candidate

2023-12-04 07:46:49 ET

Alterity Therapeutics ( NASDAQ: ATHE ) shares rallied on Monday after the biotech firm reported positive efficacy data for its lead asset, ATH434, in a Parkinson's disease primate model.

ATH434 has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in multiple system atrophy.

The study compared daily oral doses of ATH434 (3 or 10 mg/kg) versus a vehicle (placebo) for 12-14 weeks after parkinsonian symptoms were evident. Monkeys were assessed with the Parkinson Behavior Rating Scale before, during and after dosing.

The treatment improved motor performance and general function in monkeys with experimentally induced Parkinson’s disease. The favorable impact on Parkinson’s symptoms was associated with lower iron levels in the area of pathology.

In addition, the therapy increased levels of synaptophysin, a protein marker that reflects functional connections between neurons.

Shares of Alterity ( ATHE ) rallied above 400% in premarket hours on Monday

More on Alterity Therapeutics

• Seeking Alpha’s Quant Rating on Alterity Therapeutics
• Historical earnings data for Alterity Therapeutics
• Financial information for Alterity Therapeutics

For further details see: